12,284 results match your criteria Annals Of Oncology[Journal]


Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED study.

Ann Oncol 2021 Jun 12. Epub 2021 Jun 12.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address:

Background: The phase III CHAARTED trial established upfront androgen deprivation therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate cancer (mHSPC) based on meaningful improvement in overall survival (OS). Biological prognostic markers of outcomes and predictors of chemotherapy benefit are undefined.

Patients And Methods: Whole transcriptomic profiling was performed on primary prostate cancer (PC) tissue obtained from patients enrolled in CHAARTED prior to systemic therapy. Read More

View Article and Full-Text PDF

Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.

Ann Oncol 2021 Jun 8. Epub 2021 Jun 8.

Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA. Electronic address:

Background: The pivotal phase III ASCENT trial demonstrated improved survival outcomes associated with sacituzumab govitecan (SG), an anti-Trop-2 antibody-drug conjugate linked with the topoisomerase-inhibitor SN-38, over single-agent chemotherapy of physician's choice (TPC) in previously-treated metastatic triple-negative breast cancer (mTNBC). This prespecified, exploratory biomarker analysis from the ASCENT trial evaluates the association between tumor Trop-2 expression and germline BRCA1/2 mutation status with clinical outcomes.

Patients And Methods: Patients with mTNBC refractory to or progressing after ≥2 prior chemotherapies, with ≥1 in the metastatic setting, were randomized to receive SG (10 mg/kg intravenously days 1 and 8, every 21 days) or TPC (either capecitabine, eribulin, vinorelbine, or gemcitabine) until disease progression/unacceptable toxicity. Read More

View Article and Full-Text PDF

Letter to the editor: Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.

Ann Oncol 2021 Apr 28. Epub 2021 Apr 28.

Hematology Department, Gustave Roussy, Université Paris-Saclay, Villejuif, F-94805, France; INSERM U1287, Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France; Interception Program, Personalized Cancer Prevention Center, Gustave Roussy, Université Paris-Saclay. Electronic address:

View Article and Full-Text PDF

PARP Inhibitors and Newly Second Primary Malignancies in Cancer Patients: a Systematic Review and Safety Meta-Analysis of Placebo Randomized Controlled Trials.

Ann Oncol 2021 May 4. Epub 2021 May 4.

Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of Pharmacology, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), Caen, France. Electronic address:

View Article and Full-Text PDF

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival.

Ann Oncol 2021 May 15. Epub 2021 May 15.

University Hospital Erlangen, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen, Germany.

Background: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). Here we present a new landmark in survival follow-up for a phase 3 CDK4/6 inhibitor clinical trial in patients with ABC (median [m], 56.3 months). Read More

View Article and Full-Text PDF

Erratum to 'Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group': [Annals of Oncology 30 (2019) 1221-1231].

Ann Oncol 2021 Jun 2. Epub 2021 Jun 2.

Department ofClinical Genetics, Guy and St Thomas' NHS Foundation Trust, London, UK; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK; William Harvey Research Institute, Queen Mary University of London, London, UK; Public Health England, London, UK. Electronic address:

View Article and Full-Text PDF

Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159].

Ann Oncol 2021 Jun 2. Epub 2021 Jun 2.

Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G.Pascale, Napoli, Italy.

View Article and Full-Text PDF

ESMO pays tribute to Professor José Baselga.

Ann Oncol 2021 Jul 27;32(7):823-824. Epub 2021 Apr 27.

Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, Germany.

View Article and Full-Text PDF

Targeting KRAS in non-small cell lung cancer: recent progress and new approaches.

Ann Oncol 2021 Jun 2. Epub 2021 Jun 2.

Aix Marseille University, Marseille, France; Gustave Roussy Cancer Campus, Villejuif, France.

Rat sarcoma (RAS) is the most frequently mutated oncogene in human cancer, with Kirsten rat sarcoma (KRAS) being the most commonly mutated RAS isoform. Overall, KRAS accounts for 85% of RAS mutations observed in human cancers and is present in 35% of lung adenocarcinomas. While the use of targeted therapies and immune checkpoint inhibitors (CPIs) has drastically changed the treatment landscape of advanced non-small cell lung cancer (NSCLC) in recent years, historic attempts to target KRAS (both direct and indirect approaches) have had little success, and no KRAS-specific targeted therapies have been approved to date for patients in this molecular subset of NSCLC. Read More

View Article and Full-Text PDF

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma.

Ann Oncol 2021 May 31. Epub 2021 May 31.

Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT, USA.

Background: In the phase 3 KEYNOTE-061 trial (NCT02370498), pembrolizumab did not significantly improve overall survival versus paclitaxel as second-line therapy for gastric/gastroesophageal junction (GEJ) adenocarcinoma with programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥1 tumors. The association of tissue tumor mutational burden (tTMB) status and clinical outcomes was determined, including the relationship with CPS and microsatellite instability-high (MSI-H) status.

Patients And Methods: In patients with whole exome sequencing (WES) data (420/592 [71%]; pembrolizumab, 218; paclitaxel, 202), the association of tTMB with objective response rate (ORR; logistic regression), progression-free survival (PFS; Cox proportional hazards regression), and overall survival (OS; Cox proportional hazards regression) were measured using one-sided (pembrolizumab) and two-sided (paclitaxel) P values. Read More

View Article and Full-Text PDF

Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study.

Authors:
E P Mamounas

Ann Oncol 2021 May 29. Epub 2021 May 29.

NSABP Foundation and Department of Surgery, Orlando Health Cancer Institute, Orlando, USA. Electronic address:

View Article and Full-Text PDF

Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit.

Ann Oncol 2021 May 24. Epub 2021 May 24.

Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. Electronic address:

View Article and Full-Text PDF

Association between HER2 status in residual disease and sensitivity to trastuzumab emtansine.

Authors:
K Altundag

Ann Oncol 2021 May 21. Epub 2021 May 21.

MKA Breast Cancer Clinic, Tepe Prime, Ankara, Turkey. Electronic address:

View Article and Full-Text PDF

Nutritional support during the hospital stay reduces mortality in patients with different types of cancers: secondary analysis of a prospective randomized trial.

Ann Oncol 2021 May 19. Epub 2021 May 19.

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Basel, Switzerland. Electronic address:

Background: Nutritional support in patients with cancer aims at improving quality of life. Whether use of nutritional support is also effective in improving clinical outcomes requires further study.

Patients And Methods: In this preplanned secondary analysis of patients with cancer included in a prospective, randomized-controlled, Swiss, multicenter trial (EFFORT), we compared protocol-guided individualized nutritional support (intervention group) to standard hospital food (control group) regarding mortality at 30-day (primary endpoint) and other clinical outcomes. Read More

View Article and Full-Text PDF

Genomic testing for targeted oncology drugs: hopes against hype.

Ann Oncol 2021 Jul 13;32(7):837-838. Epub 2021 May 13.

Department of Oncology and Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.

View Article and Full-Text PDF

Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria.

Ann Oncol 2021 May 13. Epub 2021 May 13.

Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, USA; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, USA.

View Article and Full-Text PDF

Trabectedin: useful in leiomyosarcoma and liposarcoma, but less so in other soft tissue sarcomas.

Authors:
S Schuetze

Ann Oncol 2021 May 6. Epub 2021 May 6.

Department of Medicine, University of Michigan, Michigan, USA. Electronic address:

View Article and Full-Text PDF

Adjuvant nivolumab for the management of pathological residual disease in esophageal or junctional tumors: a word of caution.

Ann Oncol 2021 May 4. Epub 2021 May 4.

Department of Gastroenterology, Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun, India.

View Article and Full-Text PDF

Reframing recalcitrance for small-cell lung cancer.

Authors:
F H Blackhall

Ann Oncol 2021 Jul 3;32(7):829-830. Epub 2021 May 3.

Christie Hospital NHS Trust-Medical Oncology, Manchester, UK. Electronic address:

View Article and Full-Text PDF

A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.

Ann Oncol 2021 Apr 29. Epub 2021 Apr 29.

Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France.

Background: The French Sarcoma Group assessed the efficacy, safety, and quality of life (QoL) of trabectedin versus best supportive care (BSC) in patients with advanced soft tissue sarcoma (STS).

Patients And Methods: This randomized, multicenter, open-label, phase III study included adults with STS who progressed after 1-3 prior treatment lines. Patients were randomized (1 : 1) to receive trabectedin 1. Read More

View Article and Full-Text PDF

Checkpoint inhibition: protecting against or predisposing for second primary tumors? Reply to the Letter to the Editor 'Checkpoint inhibition: protecting against or predisposing for second primary tumors?' by K. P. M. Suijkerbuijk, A. M. May and M. J. M. van Eijs.

Ann Oncol 2021 Apr 28. Epub 2021 Apr 28.

Department of Research (CRCL), Centre Léon Bérard, Lyon, France; Department of Medicine, Centre Léon Bérard & Université Claude Bernard, Lyon, France; Unicancer, Paris, France; Department of Cancer Initiation and Tumor Cell Identity, Cancer Research Center of Lyon (CRCL), Lyon, France. Electronic address:

View Article and Full-Text PDF

Practical considerations in screening for genetic alterations in cholangiocarcinoma.

Ann Oncol 2021 Apr 28. Epub 2021 Apr 28.

Istituto Nazionale Tumori 'Fondazione Giovanni Pascale' IRCCS, Naples, Italy.

Cholangiocarcinoma (CCA) encompasses diverse epithelial tumors historically associated with poor outcomes due to an aggressive disease course, late diagnosis, and limited benefit of standard chemotherapy for advanced disease. Comprehensive molecular profiling has revealed a diverse landscape of genomic alterations as oncogenic drivers in CCA. TP53 mutations, CDKN2A/B loss, and KRAS mutations are the most common genetic alterations in CCA. Read More

View Article and Full-Text PDF

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.

Ann Oncol 2021 Apr 28. Epub 2021 Apr 28.

GBG, Neu-Isenburg, Germany; Center for Haematology and Oncology Bethanien, Frankfurt, Germany.

Background: In the KATHERINE study (NCT01772472), patients with residual invasive early breast cancer (EBC) after neoadjuvant chemotherapy (NACT) plus human epidermal growth factor receptor 2 (HER2)-targeted therapy had a 50% reduction in risk of recurrence or death with adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab. Here, we present additional exploratory safety and efficacy analyses.

Patients And Methods: KATHERINE enrolled HER2-positive EBC patients with residual invasive disease in the breast/axilla at surgery after NACT containing a taxane (± anthracycline, ± platinum) and trastuzumab (± pertuzumab). Read More

View Article and Full-Text PDF